uPAR/PLAUR Proteins, Antibodies, cDNA Clones, ELISA Kits Research Reagents

All uPAR/PLAUR reagents are produced in house and quality controlled, including 19 uPAR/PLAUR Antibody, 2 uPAR/PLAUR ELISA, 26 uPAR/PLAUR Gene, 1 uPAR/PLAUR IP Kit, 3 uPAR/PLAUR Lysate, 3 uPAR/PLAUR Protein, 2 uPAR/PLAUR qPCR. All uPAR/PLAUR reagents are ready to use.

uPAR/PLAUR Protein (3)

    uPAR/PLAUR Antibody (19)

      uPAR/PLAUR ELISA Kit & Match Antibody ELISA Pair Set (2)

      uPAR/PLAUR cDNA Clone (26)


      uPAR/PLAUR Lysate (3)

        uPAR/PLAUR Background

        Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-6kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

        uPAR/PLAUR References

        • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
        • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
        • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
        • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.

        Note: Flag® is a registered trademark of Sigma Aldrich Biotechnology LP. It is used here for informational purposes only.